literature

HIV mutation literature information.

Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.

PMID: 29291935 2018 Bioorganic & medicinal chemistry

Abstract: Among them, the most promising N1-aryl-2-arylthioacetamido-benzimidazoles and N1-aryl-2-aryloxyacetamido-benzimidazoles were also tested toward a panel of single- and double-mutants strain responsible for resistance to NNRTIs, showing in vitro antiviral activity toward single mutants L100I, K103N, Y181C, Y188L and E138K.

Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.

PMID: 28099515 2017 PloS one

Table: Y188L

HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.

PMID: 28114955 2017 AIDS research and therapy

Table: Y188L/C

Table: Y188L

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

PMID: 28129253 2017 Journal of acquired immune deficiency syndromes (1999)

Result: After adjustment, participants on zidovudine at failure were more likely to have T215F, T215Y, M41L, K70R, D67N, L210W, type-1 thymidine analog, type-2 thymidine analog, and any thymidine analogue mutations (TAMs); those on tenofovir to have K65R, K70E, Y115F, and M184I; those on efavirenz to have K103N, P225H, Y188L, and L100I; and those on nevirapine to have Y181C and G190A.

Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.

PMID: 28481112 2017 Journal of medicinal chemistry

Abstract: Compound 25a was exceptionally potent against the whole viral panel, affording 3-4-fold enhancement of in vitro antiviral potency against WT, L100I, K103N, Y181C, Y188L, E138K, and K103N+Y181C and 10-fold enhancement against F227L+V106A relative to the reference drug etravirine (ETV) in the same cellular assay.

Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.

PMID: 28628334 2017 Journal of medicinal chemistry

Abstract: The new IASs 8-37 showed potent inhibition of the HIV-1 WT NL4-3 strain and of the mutant K103N, Y181C, Y188L, and K103N-Y181C HIV-1 strains.

High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.

PMID: 28750647 2017 AIDS research and therapy

Result: More than half of these mutations (K65R, D67N, K70R, L74V, V75I/S, Y115F, K219Q/E, K101E/P/H, K103N, V106AM, Y181C and Y188L/H) were significantly more prevalent (p < 0.05) in the rural settings of Limpopo than in urban Pretoria (Table 2).

Table: Y188L/H

HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study.

PMID: 29244809 2017 PloS one

Table: Y188L

HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania.

PMID: 28797181 2017 AIDS research and human retroviruses

Abstract: The most common HLRMs to NVP were K103 N, Y181C, and Y188 L.

Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.

PMID: 29074854 2017 Scientific reports

Method: Analysis of pol sequences showed that 11 of these 32 subjects (34.3%) were infected with viruses harboring major DRMs, including major resistance mutations to NRTIs such as D67N, K70R, M184V, K219Q/E, T215F, and T69N; and major resistance mutations to NNRTIs such as Y181C, K103N, V106A/M, P225H, Y188L, H221Y, V108I, L100I (Tables 2 and 3).

Method: Other major

Filtrator